Achieve Life Sciences, Inc. (NASDAQ:ACHV) Short Interest Update

Achieve Life Sciences, Inc. (NASDAQ:ACHV - Get Free Report) was the target of a large increase in short interest during the month of January. As of January 15th, there was short interest totalling 3,810,000 shares, an increase of 30.0% from the December 31st total of 2,930,000 shares. Based on an average daily volume of 153,600 shares, the days-to-cover ratio is presently 24.8 days.

Hedge Funds Weigh In On Achieve Life Sciences

A number of hedge funds and other institutional investors have recently bought and sold shares of ACHV. SG Americas Securities LLC bought a new position in shares of Achieve Life Sciences during the third quarter worth $54,000. The Manufacturers Life Insurance Company acquired a new stake in Achieve Life Sciences during the 2nd quarter worth $69,000. MetLife Investment Management LLC lifted its holdings in Achieve Life Sciences by 65.6% during the third quarter. MetLife Investment Management LLC now owns 14,993 shares of the biopharmaceutical company's stock worth $71,000 after acquiring an additional 5,939 shares in the last quarter. Verition Fund Management LLC bought a new stake in shares of Achieve Life Sciences in the third quarter worth about $113,000. Finally, Renaissance Technologies LLC increased its holdings in shares of Achieve Life Sciences by 134.2% in the second quarter. Renaissance Technologies LLC now owns 25,060 shares of the biopharmaceutical company's stock worth $118,000 after acquiring an additional 14,360 shares in the last quarter. 33.52% of the stock is owned by institutional investors.

Achieve Life Sciences Trading Up 2.0 %

Shares of ACHV stock traded up $0.07 on Thursday, reaching $3.29. 70,268 shares of the stock were exchanged, compared to its average volume of 333,201. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.78 and a quick ratio of 6.78. Achieve Life Sciences has a one year low of $2.84 and a one year high of $5.59. The stock has a market cap of $112.97 million, a PE ratio of -2.88 and a beta of 1.66. The stock has a 50 day moving average price of $3.79 and a 200 day moving average price of $4.35.

Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.10). During the same period in the previous year, the company earned ($0.34) earnings per share. Equities research analysts forecast that Achieve Life Sciences will post -1.17 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently commented on the company. RODMAN&RENSHAW upgraded Achieve Life Sciences to a "strong-buy" rating in a report on Thursday, November 14th. Rodman & Renshaw initiated coverage on shares of Achieve Life Sciences in a research report on Thursday, November 14th. They set a "buy" rating and a $12.00 price target on the stock. Four research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Buy" and an average target price of $14.80.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.